Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab.

Kaufman MD, Lee R, Norton HJ.

Mult Scler. 2011 Apr;17(4):490-4. doi: 10.1177/1352458510389103. Epub 2010 Dec 6.

PMID:
21135017
2.

Natalizumab dosage suspension: are we helping or hurting?

West TW, Cree BA.

Ann Neurol. 2010 Sep;68(3):395-9. doi: 10.1002/ana.22163.

PMID:
20818793
3.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
4.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
5.

Combination therapy in multiple sclerosis.

Conway D, Cohen JA.

Lancet Neurol. 2010 Mar;9(3):299-308. doi: 10.1016/S1474-4422(10)70007-7. Review.

PMID:
20170843
6.

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.

Eur J Neurol. 2010 Jan;17(1):31-7. doi: 10.1111/j.1468-1331.2009.02728.x. Epub 2009 Jul 9.

PMID:
19614963
7.

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.

Rudick RA, Polman CH.

Lancet Neurol. 2009 Jun;8(6):545-59. doi: 10.1016/S1474-4422(09)70082-1. Review.

PMID:
19446274
8.

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

Ellis R, Boggild M.

Mult Scler. 2009 Apr;15(4):505-8. doi: 10.1177/1352458508100967. Epub 2009 Feb 27.

PMID:
19251838
9.

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E.

Mult Scler. 2009 Jan;15(1):50-8. doi: 10.1177/1352458508096687. Epub 2008 Oct 15.

PMID:
18922831
10.

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.

Carrá A, Onaha P, Luetic G, Burgos M, Crespo E, Deri N, Halfon M, Jaacks G, López A, Sinay V, Vrech C.

Eur J Neurol. 2008 Apr;15(4):386-93. doi: 10.1111/j.1468-1331.2008.02071.x.

PMID:
18353125
11.

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O.

Eur J Neurol. 2006 May;13(5):471-4.

PMID:
16722971
12.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

N Engl J Med. 2006 Mar 2;354(9):911-23.

13.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

N Engl J Med. 2006 Mar 2;354(9):899-910.

14.

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.

Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M, Stone L, Greenberg S, Stuart D, Orav J, Stuart W, Weiner H.

Mult Scler. 2005 Oct;11(5):573-82.

PMID:
16193896
15.

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.

N Engl J Med. 2005 Jul 28;353(4):375-81. Epub 2005 Jun 9.

16.

Clinical characteristics of responders to interferon therapy for relapsing MS.

Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C.

Neurology. 2003 Jul 22;61(2):184-9. Review.

PMID:
12874396
17.

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T; Mitoxantrone in Multiple Sclerosis Study Group (MIMS).

Lancet. 2002 Dec 21-28;360(9350):2018-25.

PMID:
12504397
18.

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette RE, Butine MD, Goodkin DE.

Neurology. 2002 Sep 24;59(6):909-13.

PMID:
12297576
19.

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS.

Ann Neurol. 2001 Jul;50(1):121-7.

PMID:
11456302
20.

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA Jr, Kwoh CK.

Arthritis Rheum. 1995 Aug;38(8):1120-7.

PMID:
7639809
Items per page

Supplemental Content

Write to the Help Desk